A University of Oxford study published in The BMJ finds users of GLP-1 drugs like Ozempic regain weight and reverse heart health improvements within two years of stopping treatment.

GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is ...

New evidence shows that GLP-1–based therapies not only lower glucose levels and aid in weight loss but also reduce inflammation in the heart, kidneys, liver, and brain, revealing a broader therapeutic ...

The glucagon-like peptides (GLP-1 and GLP-2) are processed from the proglucagon polypeptide and secreted in equimolar amounts but have opposite effects on chylomicron (CM) production, with GLP-1 ...

In patients with type 2 diabetes (T2D), the use of GLP-1 receptor agonists was associated with a significantly lower risk for lung cancer than the use of DPP-4 inhibitors. GLP-1 receptor agonist use ...

Please provide your email address to receive an email when new articles are posted on . Use of GLP-1 receptor agonists in diabetes was associated with reduced risk for RA and gout. No reduction in PsA ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. GLP-1 receptor agonists reduced mortality vs. DDP-4 ...

Patients with lupus and type 2 diabetes are predisposed to a disproportionate risk of atherosclerotic cardiovascular disease and chronic kidney disease. A study of this patient population showed that ...

GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Semaglutide was associated with the strongest risk reduction. Epilepsy is an underrecognized ...

Glucagon-like peptide-2 (GLP-2) is a gut-derived hormone principally secreted by enteroendocrine L cells in response to nutrient ingestion. It plays a pivotal role in maintaining intestinal integrity ...